Search Results - "Akova, M."

Refine Results
  1. 1

    Sulbactam-containing β-lactamase inhibitor combinations by Akova, M.

    Published in Clinical microbiology and infection (01-01-2008)
    “…Sulbactam irreversibly inhibits the hydrolytic activity of β-lactamases. This compound is commercially available in combination with either ampicillin or…”
    Get full text
    Journal Article
  2. 2

    Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China by Zhang, P., Shi, Q., Hu, H., Hong, B., Wu, X., Du, X., Akova, M., Yu, Y.

    Published in Clinical microbiology and infection (01-01-2020)
    “…The aim was to investigate the activity of ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the…”
    Get full text
    Journal Article
  3. 3

    ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of rare invasive yeast infections by Arendrup, M.C., Boekhout, T., Akova, M., Meis, J.F., Cornely, O.A., Lortholary, O.

    Published in Clinical microbiology and infection (01-04-2014)
    “…The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no exception. This is…”
    Get full text
    Journal Article
  4. 4

    Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria by Akova, M., Daikos, G.L., Tzouvelekis, L., Carmeli, Y.

    Published in Clinical microbiology and infection (01-05-2012)
    “…The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health…”
    Get full text
    Journal Article
  5. 5
  6. 6

    The global threat of antimicrobial resistance: science for intervention by Roca, I, Akova, M, Baquero, F, Carlet, J, Cavaleri, M, Coenen, S, Cohen, J, Findlay, D, Gyssens, I, Heure, O.E, Kahlmeter, G, Kruse, H, Laxminarayan, R, Liébana, E, López-Cerero, L, MacGowan, A, Martins, M, Rodríguez-Baño, J, Rolain, J.-M, Segovia, C, Sigauque, B, Tacconelli, E, Wellington, E, Vila, J

    Published in New microbes and new infections (01-07-2015)
    “…Abstract In the last decade we have witnessed a dramatic increase in the proportion and absolute number of bacterial pathogens resistant to multiple…”
    Get full text
    Journal Article
  7. 7

    Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control by Carmeli, Y., Akova, M., Cornaglia, G., Daikos, G.L., Garau, J., Harbarth, S., Rossolini, G.M., Souli, M., Giamarellou, H.

    Published in Clinical microbiology and infection (01-02-2010)
    “…Although the rapid spread of carbapenemase-producing Gram-negatives (CPGNs) is providing the scientific community with a great deal of information about the…”
    Get full text
    Journal Article
  8. 8

    Multidrug-resistant bacteria in solid organ transplant recipients by Cervera, C., van Delden, C., Gavaldà, J., Welte, T., Akova, M., Carratalà, J.

    Published in Clinical microbiology and infection (01-09-2014)
    “…Bacteria are the leading cause of infections after solid organ transplantation. In recent years, a progressive growth in the incidence of multidrug-resistant…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients by De Waele, Jan J., Lipman, J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Udy, A. A., Starr, T., Wallis, S. C., Roberts, J. A.

    Published in Intensive care medicine (01-09-2014)
    “…Purpose Risk factors for β-lactam antibiotic underdosing in critically ill patients have not been described in large-scale studies. The objective of this study…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Leading infectious diseases problems in Turkey by Erdem, H., Akova, M.

    Published in Clinical microbiology and infection (01-11-2012)
    “…Turkey has significant geographical and socio-economic differences throughout a vast area of the country. These characteristics affect the epidemiology of…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Mixed fungaemia: an 18-year report from a tertiary-care university hospital and a systematic review by Gülmez, D., Alp, S., Gursoy, G., Ayaz, C.M., Dogan, O., Arikan-Akdagli, S., Akova, M.

    Published in Clinical microbiology and infection (01-07-2020)
    “…While fungaemia caused by two or more different species of yeasts (mixed fungaemia, MF) is infrequent, it might be underestimated. This study aimed to…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20